Inactive Instrument

Press Releases Fresenius SE & Co. KGaA Other OTC

Equities

Fresenius : successfully completes divestment of hospital stake in Peru	Apr. 23	PU
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne, its Third Approved Biosimilar in the U.S.	Apr. 16	AQ
Fresenius : Investor Relations Company Presentation	Apr. 12	PU
Fresenius : Chairman Letter	Apr. 07	PU
Fresenius : MAbxience and Teva announce strategic global license agreement for biosimilar oncology treatment	Apr. 04	PU
Fresenius : Management Board buys own shares	Apr. 04	PU
DD: Fresenius SE & Co. KGaA: Robert Möller, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Sara Hennicken, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Pierluigi Antonelli, buy	Apr. 04	EQ
DD: Fresenius SE & Co. KGaA: Michael Sen, buy	Apr. 04	EQ
AGM: Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution	Apr. 02	EQ
Fresenius : Meeting Participation by individual Supervisory Board member 2023	Apr. 01	PU
Fresenius : 2023 SASB Index	Apr. 01	PU
Fresenius : 2023 TCFD Index	Apr. 01	PU
Fresenius : 2023 ESG KPI Overview	Mar. 21	PU
Fresenius : Kabi and Formycon reach settlement agreement for ustekinumab biosimilar candidate	Mar. 18	PU
Fresenius : Financial Statements 2022 (HGB)	Mar. 14	PU
Fresenius : Participations in affiliated and associated companies 2023	Mar. 14	PU
Fresenius : Annual Report 2023 (IFRS)	Mar. 14	PU
DD: Fresenius SE & Co. KGaA: Dr. Frank Appel, buy	Mar. 13	EQ

No results for this search

FRESENIUS : A good ending does not allow for extreme optimism in 2024

February 22, 2024 at 07:42 am EST